Roel Straetemans

ADJUSTING PAIRWISE NONPARAMETRIC EQUIVALENCE HYPOTHESIS TESTS AND CONFIDENCE INTERVALS FOR PERIOD EFFECTS IN 3×3 CROSSOVER TRIALS

P. Janssen, L. Duchateau, C. Otoul, 2002, Journal of biopharmaceutical statistics.

MODELING ANTI-KLH ELISA DATA USING TWO-STAGE AND MIXED EFFECTS MODELS IN SUPPORT OF IMMUNOTOXICOLOGICAL STUDIES

G. Molenberghs, Z. Shkedy, L. Bijnens, 2005, Journal of biopharmaceutical statistics.

Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data

Vikash K. Sinha, L. Bijnens, C. Mackie, 2011, Clinical pharmacokinetics.

The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.

F. Cools, D. Gallacher, K. van Ammel, 2009, Journal of pharmacological and toxicological methods.

A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.

M. Mercken, F. De Ridder, L. Dillen, 2012, Journal of Alzheimer's disease : JAD.

MODELING ANTI-KLH ELISA DATA USING TWO-STAGE AND MIXED EFFECTS MODELS IN SUPPORT OF IMMUNOTOXICOLOGICAL STUDIES.

G. Molenberghs, Z. Shkedy, L. Bijnens, 2005, Journal of biopharmaceutical statistics.

Model-Based Approaches

Z. Shkedy, W. Talloen, H. Göhlmann, 2012 .

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques

H. Schuitemaker, N. Guimerà, F. Wegmann, 2021, bioRxiv.

Levetiracetam: Relative Bioavailability and Bioequivalence of a 10% Oral Solution (750 mg) and 750‐mg Tablets

A. Stockis, Roel Straetemans, Z. Lu, 2003, Journal of clinical pharmacology.